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Consent and 
criminalisation concerns 
over phylogenetic 
analysis of surveillance 
data
As scholars and advocates, including 
people living with HIV, we are 
responding to the publication of 
Ragonnet­Cronin and colleagues’ 
phylogenetic analysis in Los Angeles 
County (CA, USA)1 to express 
our concern about a problematic 
turn in HIV surveillance research. 
Activists, legal experts, and social 
scientists are increasingly concerned 
about the rights, consent, and 
privacy implications of “molecular 
surveillance”, which risks reducing 
people living with HIV to vectors 
of disease. A seemingly benign 
focus on molecules, with data 
repurposed from routine care, used 
secondarily without patient consent, 
and cross­referenced with other 
data sources, allows for laboratory 
identification of sexual HIV trans­
mission networks. Did these women 
consent to their health data being 
used in this manner? The study 
positions transgender women at the 
centre of high­risk sexual networks; 
a particular concern in the USA, where 
there is heightened criminalisation 
of sex work, migration, drug use, and 
HIV. Although phylogenetic analysis 
cannot, and should not, be used to try 
and prove transmission directionality, 
it has been used to criminalise people, 
and to intervene in their lives, with 
serious consequences. Not only are 
the study results already known to 
transgender women and other experts 
working on the ground—that their 
sexual networks are different from 
men who have sex with men—the 
myriad of reasons why transgender 
women may be out of reach of public 
health authorities (eg, discrimination 
from health­care workers, by choice, 
fears of criminal isation) are also 
overlooked by the authors.  
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Authors’ reply
We appreciate the opportunity 
to broaden the discussion of HIV 
surveillance. Our study analysed de­
identified data collected under the 
auspices of public­health surveillance. 
When individuals are diagnosed 
with HIV in the USA, pertinent data, 
including viral genetic sequences, 
are reported to public­health 
departments. These data are protected 
by statute to guard individual 
confidentiality. HIV surveillance—
which includes data collection, 
analysis, and interpretation—is 
integral to improving and allocating 
services for people living with and 
at­risk of HIV.1 This approach helps 
public­health officials improve services 
for groups disproportionately affected 
by HIV, such as transgender women.
To ask whether individuals in our 
analysis consented to their data being 
used to identify HIV transmission 
clusters begs the question of 
whether consent is imperative to HIV 
surveillance. Surveillance for numerous 
infectious agents, including HIV, is 
done ethically and without consent.2 
The public good of HIV surveillance 
justifies this approach. Requiring 
consent for surveillance reporting 
would preclude a robust understanding 
of disease distribution and spread and 
the ensuing benefit to the health of 
individuals and communities.
The ethics of HIV surveillance have 
been debated long before studies of 
HIV genetic transmission networks, 
partly because some data (eg, diagnosis 
date and named sexual partners) have 
potential use in criminal prosecution. 
Our study was approved by university 
and public­health department insti­
tutional review boards. Although 
California recently modernised its 
HIV criminalisation laws,3 these laws 
do vary by geography. Furthermore, 
we acknowledge that viral genetic 
analysis carries heightened risks and 
concomitant ethical burden. Thus, we 
take part in ongoing discussions of 
ethics with scientists, public­health 
officials, legal experts, and community 
members.4,5
Our  study quanti f ied  the 
population­level relation between 
transgender women and people 
reporting other risk factors in HIV 
transmission clusters. To clarify, 
we neither put forth claims about 
the sexual networks of transgender 
women nor about their position at 
the centre of these networks. We did, 
however, detail how genetic analysis 
can be used to direct public­health 
services to transgender women by 
prioritising their cisgender genetic 
partners.6 Molecular epidemiology 
can play a part in bringing an end 
to the HIV epidemic,1 and it can 
be used ethically in a public health 
framework.
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Estimating fiscal space 
for health: pitfalls and 
solutions
Authors’ response
We appreciate Olivier Sterck’s 
examination of our analysis1 and 
thank him in particular for extolling 
our estimates as a public good useful 
for researchers and policy makers 
alike; however, several critiques of our 
analysis were made that we believe 
are misinterpretations of our stated 
aims. 
Sterck’s first concern is that our 
potential government spending 
estimates were “not compared with 
the amount that countries would 
actually need to pay to efficiently 
confront the HIV/AIDS epidemic”. For 
the benchmark proposed by Sterck 
to be relevant, one must assume 
that HIV/AIDS programmes can be 
efficiently scaled up to confront the 
HIV/AIDS epidemic. However, Stover 
and colleagues’ analysis of resources 
needed—which was used in both our 
and Sterck’s analyses—humbly admits 
their estimates include “significant 
uncertainty” and do not capture 
the real­life inefficiencies associated 
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with the scaling up of HIV/AIDS 
programmes.2 Further, Stover and 
colleagues put forth estimates of 
the annual resources needed to keep 
pace with a scale­up schedule that 
meets global goals. If countries have 
the available resources to confront 
the HIV/AIDS epidemic sooner rather 
than later, there is no reason for them 
to be tied to the schedule proposed 
by Stover and colleagues. For these 
two reasons, we feel it would be 
limiting to constrain our estimates 
of potential spending using Stover 
and colleagues’ estimated resource 
needs. Presenting what governments 
could spend is likely more useful 
to decision makers as they face 
the reality of scaling up HIV/AIDS 
programmes and are operating with 
some inefficiencies. Second, not 
comparing our estimates against 
existing benchmarks does not bias 
the results; it is merely a choice made 
when determining how to report 
our estimates. Our estimates report 
what we believe governments could 
spend on HIV/AIDS and purposefully 
avoid thorny issues surrounding 
measurement of what countries 
should spend. 
Sterck’s second concern centres 
on variable selection for our models, 
assuming we are operating from the 
perspective of governments, that 
seemingly control tax policy, resource 
allocation across sectors and within 
the health sector. This assumption 
leads him to suggest we should not 
have included covariates such as the 
level of the health budget, overall 
government budget, or current 
economic growth as governments 
have control over these inputs. On 
the contrary, we adopted for our 
analysis the more focused perspective 
of a ministry of health. We stated 
explicitly that we “estimate the 
potential for governments to spend 
additional resources on HIV/AIDS, 
relative to their fixed health budget 
and other public finance, economic, 
and contextual factors”. Because 
ministries of health typically have 
little control over the magnitude 
of their budget, tax revenue, or 
economic growth, Sterck’s first rule 
of covariate selection suggests that 
these variables should be included in 
the analysis, as we have.
Sterck’s third rule of covariate 
inclusion suggests that contextual 
variables should be included within 
the analysis. Following this rule, 
we included HIV/AIDS mortality 
and incidence in our modelling, as 
these covariates highlight critical 
contextual factors when pondering 
the amount of resources to spend 
on the epidemic. Although we agree 
with Sterck that including these 
variables could lead to endogeneity, 
we believe the endogeneity was 
minimal, as it is commonly thought 
that investments in health impact 
health outcomes with some time lag,3 
because programmes take time to 
be implemented and scaled up and 
to have measurable health impacts. 
If this is the case, the inclusion of 
contemporaneous HIV/AIDS mortality 
and incidence would not significantly 
bias our results. 
We fully agree with Sterck 
and his assessment that, taken 
together, inclusion of the wide array 
of covariates offers a conservative 
estimate of potential spending. As 
presented in the supplementary 
appendix and stated in our discussion, 
“our estimates are on average less 
than 50% of previous estimates”. This 
indicates that our estimates are on 
the conservative end, which we feel is 
prudent and responsible.
Lastly, Sterck suggests that quantile 
regressions could be an alternative to 
the stochastic frontier analysis (SFA) 
method used in our analysis. We 
agree that use of quantile regressions 
is a promising advance but believe 
the method requires more vetting 
for it to displace SFA as a dominant 
method in efficiency analyses. More 
guidance is needed in the selection 
of which quantile to estimate the 
regressions at (eg, 75%, 80%, or 95%), 
and the ramifications of this selection 
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